Mark Lanasa

Mark Lanasa, M.D., Ph.D., joined BeiGene in 2022 as Senior Vice President, Chief Medical Officer for Solid Tumors. Prior to BeiGene, Dr. Lanasa served as Vice President and Global Clinical Head, Late Development Oncology at AstraZeneca and held a number of positions of increasing responsibility, including Global Clinical and Development Lead for Immuno-Oncology. He also worked in Clinical Development at Immunocore. Mark earned his B.S. in chemistry from Pennsylvania State University, and his Ph.D. in biochemistry and molecular genetics and M.D. in the Medical Scientist Training Program at the University of Pittsburgh School of Medicine. He completed his residency and was a post-graduate fellow at the Duke University Medical Center, where he was on the faculty in hematologic malignancies.